ERAS
Erasca, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Erasca, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+1.47%
vs ±13.2% implied · ×0.11
shaded = implied · ▲▼ = realized
| Manager | Value | % base | |
|---|---|---|---|
| Frazier Life Sciences | $457.5M | 8.64% | +1.22% |
| T. Rowe Price | $388.1M | 7.33% | −0.35% |
| BlackRockindex-like | $387.5M | 7.32% | +4.98% |
| RTW | $328.8M | 6.21% | +11.08% |
| VR Adviser | $327.8M | 6.19% | +9.21% |
| Manager | Value | % base | |
|---|---|---|---|
| Frazier Life Sciences | $457.5M | 8.64% | +1.22% |
| T. Rowe Price | $388.1M | 7.33% | −0.35% |
| BlackRockindex-like | $387.5M | 7.32% | +4.98% |
| RTW | $328.8M | 6.21% | +11.08% |
| VR Adviser | $327.8M | 6.19% | +9.21% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Erasca, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Erasca, Inc.'s 6 closest co-movers, none share that code.
Bull2
Bear1
Tall tick = annual report · Source: EDGAR
Erasca, Inc.
14.91
+0.27 · +1.83%
post 15.71 +5.38%
Expected move
Inputs8Q avg ±3.4%·×3.43·rich
straddle ±17.5%
spot 14.91exp Nov 20ATM strike 15ATM straddle 3.07IV 118%